×
About 3,623 results

ALLMedicine™ Gastrointestinal Stromal Tumors Center

Research & Reviews  1,220 results

Clinicopathological features, clinical efficacy on 101 cases of rectal gastrointestinal...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603575
BMC Surgery; Yang H, Shen C et. al.

Nov 21st, 2021 - To investigate the clinicopathological features and clinical efficacy among 101 cases of rectal gastrointestinal stromal tumors (GISTs) and to investigate the significance of imatinib mesylate (IM) neoadjuvant therapy. The clinicopathological feat...

Incidental Gastrointestinal Stromal Tumors (GIST) During Laparoscopic Sleeve Gastrectom...
https://doi.org/10.1007/s11695-021-05770-7 10.3748/wjg.14.821 10.1007/s00595-007-3648-8 10.1007/s11695-019-03782-y 10.1002/ccr3.2093 10.5114/wiitm.2017.70215 10.1007/s11695-015-1571-4 10.7326/0003-4819-115-12-956 10.1055/s-2004-860867 10.1016/j.soard.2015.06.004 10.1245/s10434-015-4520-5 10.1007/s11695-015-1983-1 10.4251/wjgo.v5.i6.102 10.5114/wiitm.2017.67807
Obesity Surgery; Hallak YO, Karajeh O et. al.

Nov 12th, 2021 - Gastrointestinal stromal tumors (GIST) are the most frequently occurring form of mesenchymal tumors in the gastrointestinal tract. Laparoscopic sleeve gastrectomy (LSG) is a commonly performed bariatric operation in which a portion of the gastric ...

Laparoscopic Versus Open Surgery for Rectal Gastrointestinal Stromal Tumor: A Multicent...
https://doi.org/10.1097/DCR.0000000000002014
Diseases of the Colon and Rectum; Jia J, Wang M et. al.

Nov 12th, 2021 - The safety and feasibility of laparoscopic surgery for the management of rectal gastrointestinal stromal tumors are unknown. To compare the surgical and oncologic results of laparoscopic versus open surgery for the treatment of rectal gastrointest...

Fully Laparoscopic Pancreas-Preserving Resection of the Third and Fourth Portion of the...
https://doi.org/10.1089/lap.2021.0480
Journal of Laparoendoscopic & Advanced Surgical Technique... Portale G, Mazzeo A et. al.

Nov 12th, 2021 - Background: Infra-ampullary duodenal lesions are rare and surgical management is controversial. The commonly accepted treatment, which allows radical resection, is pancreaticoduodenectomy, but segmental duodenal resection has been considered as al...

see more →

Guidelines  4 results

Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295840
World Journal of Gastroenterology; Li J, Wang M et. al.

Dec 26th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal str...
https://doi.org/10.1093/annonc/mdu360
Annals of Oncology : Official Journal of the European Soc... Bellera CA, Penel N et. al.

Jul 30th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treat...
https://doi.org/10.1093/annonc/mds252
Annals of Oncology : Official Journal of the European Soc...

Nov 20th, 2012 - Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012| ,|therapeutic use,diagnosis,genetics,therapy,diagnosis,genetics,therapy,therapeutic use,therapeutic use,

Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment...
https://doi.org/10.1093/annonc/mdn080
Annals of Oncology : Official Journal of the European Soc... Casali PG, Jost L et. al.

May 9th, 2008 - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Casali PG,Jost L,Reichardt P,Schlemmer M,Blay JY,|diagnosis,epidemiology,pathology,therapy,

see more →

Drugs  1 results see all →

Clinicaltrials.gov  46 results

Study in Low Risk Gastrointestinal Stromal Tumor (GISTs)
https://clinicaltrials.gov/ct2/show/NCT04599660

Nov 1st, 2021 - In the field of soft tissue sarcomas, Gastrointestinal Stromal Tumors (GIST) represents a really peculiar neoplasm for its biological and clinical properties. Surgery (if feasible) is the main therapeutic approach for all the patients with localiz...

Regorafenib Post-marketing Surveillance in Japan
https://clinicaltrials.gov/ct2/show/NCT01933958

Oct 26th, 2021 - This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Regorafenib for gastrointestinal stromal tumors progressed after cancer chemotherapy. A total of 1...

Study On Safety Of Endoscopic Resection For 2-5cm Gastric Gastrointestinal Stromal Tumor
https://clinicaltrials.gov/ct2/show/NCT04751591

Oct 22nd, 2021 - Gastrointestinal stromal tumors (GIST) originate from interstitial cells of Cajal (ICC) and are the most common tumors derived from mesenchymal tissues of the digestive tract. GISTs can occur in any part of the digestive tract, among which gastric...

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogen...
https://clinicaltrials.gov/ct2/show/NCT03165721

Jul 30th, 2021 - Background Loss of activity of the Krebs cycle components succinate dehydrogenase (SDH) complex or fumarate hydratase (FH), has been identified as a mechanism of tumorigenesis in subsets of gastrointestinal stromal tumor (GIST), pheochromocytoma a...

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02508532

Jul 2nd, 2021 - This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult...

see more →

News  175 results

Dr. Trent on the Role of ctDNA in Soft Tissue Sarcoma
https://www.onclive.com/view/dr-trent-on-the-role-of-ctdna-in-soft-tissue-sarcoma

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the role of circulating tumor DNA (ctDNA) in soft tissue sarcoma.  ctDNA...

Dr. D’Amato on the Limitations of Liquid Biopsy in Sarcoma
https://www.onclive.com/view/dr-d-amato-on-the-limitations-of-liquid-biopsy-in-sarcoma

Oct 6th, 2021 - Gina Z. D'Amato, MD, associate professor and assistant director of Clinical Research, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the limitations of liquid biopsy in sarcoma. In August 2020, the FDA appro...

Dr. Trent on the Potential Role of Immunotherapy in GIST
https://www.onclive.com/view/dr-trent-on-the-potential-role-of-immunotherapy-in-gist

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD, professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses the potential role of immunotherapy in gastrointestinal stromal tumors (G...

Dana-Farber Cancer Institute Establishes the David Liposarcoma Research Initiative
https://www.onclive.com/view/dana-farber-cancer-institute-establishes-the-david-liposarcoma-research-initiative

Aug 19th, 2021 - Dana-Farber Cancer Institute announced that The Rossy Foundation has committed $10 million to establish the David Liposarcoma Research Initiative. The five-year initiative will spearhead groundbreaking research into liposarcoma at Dana-Farber and ...

Avapritinib Does Not Show PFS Benefit Over Regorafenib in Late-Line GIST, But Remains Active Option for Select Subset
https://www.onclive.com/view/avapritinib-does-not-show-pfs-benefit-over-regorafenib-in-late-line-gist-but-remains-active-option-for-select-subset

Aug 6th, 2021 - Avapritinib (Ayvakit) did not improve progression-free survival (PFS) vs regorafenib (Stivarga) in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST), but the agent continues to be the most active available option for ...

see more →

Patient Education  3 results see all →